In these studies we demonstrate that Pax9 is upstream of Wnt signaling during 23 palatogenesis. Our gene expression analyses and molecular assays demonstrate that 24 the inhibitors of Wnt expression, namely, Dkk1 and Dkk2 directly interact with Pax9 25 offering an explanation for why these genes are down regulated in Pax9 mutant palatal 26 mesenchyme. The controlled intravenous delivery of Wnt agonist small molecules to 27 pregnant Pax9 +/-mice consistently corrects cleft palate defects in mutant progeny thus 28 confirming that the Pax9-Wnt signaling pathway is a critical regulator of palatogenesis. 29
Results 1
Dkk1, Dkk2 and Pax9 expression in posterior palatal mesenchyme differ from that of 23 ( Fig. 2G-N) . At E13.5, Dkk1 expression was detected in the posterior palatal 27 mesenchyme with a buccal to lingual gradient pattern (Fig. 2H) . In Pax9 mutant 28 samples, Dkk1 expression was increased in the posterior palate and extended to 29 anterior region (Fig. 2I,J) . Dkk2 expression was higher in the posterior palatalmesenchyme with lingual to buccal gradient (Fig. 2L) , and increased in the Pax9 mutant 1 samples ( Fig 2N) . 2 3
In order to elucidate the nature of the putative upstream relationship of Pax9 to the Wnt 4 inhibitors, we performed ChIP-qPCR analysis. Fig. 3B ,C shows that Pax9 directly 5 interacts with promoters of Dkk1 and Dkk2 and that its binding was enriched 3-to 6-fold 6 when compared to negative controls (Fig. 3B,C) . Taken together, these data suggest 7
for the first time that Pax9 shares a direct upstream molecular relationship with Wnt 8 inhibitor genes during key stages in palatogenesis. 9
10
Small molecule Wnt agonists that act as Dkk inhibitors cure cleft palate defects in 11
Pax9
-/-mice confirming that the Pax9/Wnt pathway is critical in palatogenesis 12
We assessed whether the intravenous (IV) administration of small-molecules that 13 exclusively target the Wnt pathway can correct palatal defects that are a consistent 14 +/-mice from E10.5 to 17 E14.5 covering the palatal stages of initiation, outgrowth and elevation (Fig. 4) . The 18 delivery of 5 doses of WAY-262611 (Fig. S1A ) at either level resulted in fusion of the 19 secondary palate in all (18/18) Pax9 -/-pups examined. Treatment from E10.5 to E13.5 20 rescued the cleft phenotype, but to a lesser extent than the E10.5 to E14.5 regimen 21 (Table. 2). As disclosed in Table 2 , 60% (11/18) additionally displayed complete fusion 22 between the primary and secondary palates while 7/18 showed small residual defects in 23 the zone of fusion of the primary and secondary palates around the 3 rd rugae (Fig. S2B) . 24
Since Pax9 -/-pups die postnatally, E18.5 palatal shelves with small-sized fusion defects 25 after treatment with WAY-262611 were cultured: 3 days later, all palates displayed 26 complete fusion (Fig. S2 ). This suggests that the lack of complete fusion was due to a 27 timing delay rather than to genetic differences between the primary and secondary 28
palates. 29
We tested another small-molecule agonist of Wnt signaling, IIIc3a, that blocks the Wnt 1 antagonists Dkk1, 2 and 4 (Li et al., 2012) (Fig. S1B) . Daily IV delivery of IIIc3a to 2 pregnant dams from E10.5 to E14.5 resulted in secondary palate fusion in 80% (12/15) 3 of Pax9 -/-pups and palate closure in 40% (6/15). Hematoxylin & eosin as well as 4
Masson's trichrome stains revealed that both pharmacological interventions brought 5 about a true correction of the secondary palatal defect and the deposition of collagen-6 enriched matrix in the area of the midline (Fig. 5) . The sample size for each treatment 7 group were confirmed by power analysis using PASS software, version 11 (Hintze, J. 8 (2011). PASS 11. NCSS, LLC. Kaysville, Utah, USA) provided by University of Utah 9
Study Design and Biostatistics Center to reach power > 80%. 10
11
Since Pax9 regulates Msx1, a transcription factor that also plays a role in palatogenesis, 12
IV injections of WAY-262611 and III3ca at 25 mg/kg were given to pregnant Msx1 +/-13 mice, but this failed to rescue cleft palate defects in mutant pups (0/50) ( (Table 3) . WAY-262611 had no effect on Dkk1 and Dkk2 mRNA levels, because 26 it acts at the protein level. As an indicator of restored Wnt signaling after treatment, real-27 time PCR result shows that the 6-fold level in reduction of Gbx2 and L1cam, which are 28 direct Wnt target genes, were partially rescued (Fig. 6B) the onset of renewed bone formation in these areas (Fig. 8A,B) . Alkaline phosphatase is 17 an early osteoblast differentiation marker, which was activated in the osteoprogenitor 18 cells of the palatal mesenchyme at E15.5 in the wildtype control embryos. However, no 19 alkaline phosphatase activity was detected in the palate of Pax9 mutant embryos. After 20
Wnt agonist treatment, enzymatic activity was restored in the Pax9 mutant palate (Fig.  21   8A) . Col1a1, a marker of differentiated osteoblasts appeared in osteoblasts within 22 osteogenic zones as early as E15.5 and increased from E16.5 to E18.5 in the wildtype 23 embryos. In contrast, Pax9 mutant samples failed to show Col1a1 expression in 24 putative mesenchyme. After Wnt agonist treatment, Col1a1 expression was restored as 25 indicated by the osteogenic activity within the palatal shelves (Fig. 8B) . 26
27
Taken together, these data establish that the IV delivery of small-molecule Wnt agonists 28 to pregnant Pax9 +/-females within a critical gestational window was effective in bringing 29 about successful closure of the palatal shelves in Pax9 -/-embryos (Fig. 8) . While Wntdevelopmental arrest of tooth organs, thymus, parathyroid glands and hind limb defects 1 in treated mutants (Fig. S4) These studies explored, for the first time, the nature of the molecular relationship 10 between Pax9 and Wnt genes in palatogenesis. We provide definitive evidence that 11
Pax9 deficiency alters Wnt expression activity in palatal shelves. We confirm that Pax9 12 shares a direct upstream relationship with the Wnt pathway as the transcription factor 13 can directly bind to the promoters of Dkk1 and Dkk2, proteins that inhibit the binding of 14 
14
and BAT-Gal mice were maintained in C57BL/6 background, 2-8 months old females 15 were used for intercross mating, mice for testing toxic effects were 18 months old. 16
17

Gene expression analysis 18
Whole transcriptome profiling of the developing palatal shelves were analyzed by RNA-19 Seq as previously described (Jia et al., 2013). In brief, total RNAs were extracted from 20 individual palatal shelves using the RNeasy Micro Kit (Qiagen). cDNA templates were 21 generated using the Illumina TruSeq RNA Sample Prep Kit v2 with oligo(dT) selection. 22
Sequenced reads were mapped to the reference mouse genome (mm10) using 23 Novoalign (v2.08.03). Read counts were generated using USeq's Defined Region 24
Differential Seq application and normalized counts were used in DESeq2 to measure 25 differential expression. The RNA-seq raw data have been deposited into Gene 26 Expression Omnibus database (GEO) (http://www.ncbi.nlm.nih.gov/geo) under 27 accession number GSE89603. The candidate genes were screened from a comparison 28 of 5 sets of data through the procedure below: First, the normalized counts were cut-off 29 at 10 in at least one of the samples, then the fold change was chosen at 1.5-fold or 30 higher and at P-values <0.01 from the Audic Claverie test with Benjamini Hochberg(https://toppgene.cchmc.org) for functional enrichment analysis. 3 total RNA was extracted individually using the RNeasy Micro Kit (Qiagen). First-strand 7 cDNA was synthesized using the SuperScript First-Strand Synthesis System 8 (Invitrogen). Quantitative PCRs were performed in a StepOnePlus TM Real-Time PCR 9
System (Applied Biosystems) using the SYBR Green ER qPCR Supermix (Invitrogen). 10
Gene-specific primers are listed in the supplemental data. For each sample, the relative 11 levels of target mRNAs were normalized to HPRT using the standard curve method. 5 12 sets of samples were analyzed for each gene. Student's t-test was used to analyze 13 differences and P values <0.05 considered statistically significant. 14 15
Delivery of Small-Molecule Wnt Pathway agonists 16
Two small molecules agonists were used to treat the timed pregnant female mice. 17 WAY-262611, (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine, is a 2-18 aminopyrimidine compound (Fig. S1A) assay. IIIc3a, 9-Carboxy-3-(dimethyliminio)-6,7-dihydroxy-10-methyl-3H-phenoxazin-10-22 iumiodide, is an enhanced in-solution stable gallocyanine analog (Fig. S1B) 
ChIP-qPCR assay 17
The plasmid pCMV-Tag3B-Pax9 was transfected into HEK293T cells (From ATCC). with RIPA buffer, LiCl buffer and TE buffer, bound complexes were eluted by heating at 25 65°C and crosslinking was reversed by overnight incubation at 65°C. After purified by 26
Agencourt AMPure XP beads (Beckman Coulter, A63880), the concentration was 27 determined by Qubit 3.0 Fluorometer (Thermo Fisher). 0.2 ng of each DNA sample was 28 used for qPCR analysis. The primer sequences for Dkk1 and Dkk2 promoter regions 29 that were used in the qPCR are listed in the supplemental data.
Whole palate shelf organ culture 1
The WAY-262611 treated palates were dissected on ice by removing the lower jaw and 2 brain, samples with residual fusion defects were marked and cultured as previously 3 described (Almaidhan et al., 2014) . Pax9 +/-and untreated Pax9 -/-embryos were cultured 4 as control. The dissected E18.5 palate shelves were put into 2 ml of medium (CO2 5 independent medium, Invitrogen, #18045-088; 20% FBS; 1X antimycotic-antibiotic, 6
Invitrogen, #15240-096). Culture tubes were rotated 12 rpm at an angle of 20 degree in 7 a 37°C incubator for 3 days with daily media changes. After pictures taken with a 8 stereomicroscope, tissues were fixed and embedded for histologic analyses. At least 5 9
replicates of each treatment and genotype were utilized for culture experiments. The expression levels were shown by normalized counts. FC, Fold Change; -, down-4 regulation. 5 6 The expression levels were shown by normalized counts. FC, Fold Change; -, down-4 regulation; *, p-value < 0.01; WAY, WAY-262611 treatments; CTR, control treatments; prospective palatal processes of the palatine bone. n=5 for each assay.
